These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24220936)

  • 1. Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.
    Krzakowski M; Bennouna J; Dansin E; Kowalski D; Hiret S; Penel N; Favrel S; Tourani JM
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):231-6. PubMed ID: 24220936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
    Davies AM; Ho C; Hesketh PJ; Beckett LA; Lara PN; Lau DH; Gandara DR
    Invest New Drugs; 2007 Aug; 25(4):351-5. PubMed ID: 17440682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.
    Sanoff HK; Davies JM; Walko C; Irvin W; Buie L; Keller K; Ivanova A; Chiu WK; O'Neil BH; Stinchcombe TE; Dees EC
    Invest New Drugs; 2011 Oct; 29(5):978-83. PubMed ID: 20387090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
    Reckamp K; Gitlitz B; Chen LC; Patel R; Milne G; Syto M; Jezior D; Zaknoen S
    Cancer; 2011 Feb; 117(4):809-18. PubMed ID: 20922800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
    Smith DA; Conkling P; Richards DA; Nemunaitis JJ; Boyd TE; Mita AC; de La Bourdonnaye G; Wages D; Bexon AS
    Cancer Immunol Immunother; 2014 Aug; 63(8):787-96. PubMed ID: 24770667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
    Felip E; Ranson M; Cedrés S; Dean E; Brewster M; Martínez P; McNally V; Ross G; Galdermans D
    Clin Lung Cancer; 2012 Nov; 13(6):432-41. PubMed ID: 22609229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules.
    Sutiman N; Zhang Z; Tan EH; Ang MK; Tan SW; Toh CK; Ng QS; Chowbay B; Lim WT
    PLoS One; 2016; 11(5):e0154316. PubMed ID: 27135612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
    Riely GJ; Rizvi NA; Kris MG; Milton DT; Solit DB; Rosen N; Senturk E; Azzoli CG; Brahmer JR; Sirotnak FM; Seshan VE; Fogle M; Ginsberg M; Miller VA; Rudin CM
    J Clin Oncol; 2009 Jan; 27(2):264-70. PubMed ID: 19047285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
    Otani S; Hamada A; Sasaki J; Wada M; Yamamoto M; Ryuge S; Takakura A; Fukui T; Yokoba M; Mitsufuji H; Toyooka I; Maki S; Kimura M; Hayashi N; Ishihara M; Kasajima M; Hiyoshi Y; Katono K; Asakuma M; Igawa S; Kubota M; Katagiri M; Saito H; Masuda N
    Am J Clin Oncol; 2015 Aug; 38(4):405-10. PubMed ID: 26214085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer.
    Souquet PJ; Krzakowski M; Ramlau R; Sun XS; Lopez-Vivanco G; Puozzo C; Pouget JC; Pinel MC; Rosell R
    Clin Lung Cancer; 2010 Mar; 11(2):105-13. PubMed ID: 20199976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
    Padda SK; Krupitskaya Y; Chhatwani L; Fisher GA; Colevas AD; San Pedro-Salcedo M; Decker R; Latz JE; Wakelee HA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1013-20. PubMed ID: 22160298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
    Yamamoto N; Murakami H; Hayashi H; Fujisaka Y; Hirashima T; Takeda K; Satouchi M; Miyoshi K; Akinaga S; Takahashi T; Nakagawa K
    Br J Cancer; 2013 Nov; 109(11):2803-9. PubMed ID: 24169346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
    Padda SK; Reckamp KL; Koczywas M; Neal JW; Kawashima J; Kong S; Huang DB; Kowalski M; Wakelee HA
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):105-115. PubMed ID: 34773474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
    Soria JC; LoRusso P; Bahleda R; Lager J; Liu L; Jiang J; Martini JF; Macé S; Burris H
    Oncologist; 2015 Mar; 20(3):245-6. PubMed ID: 25669662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
    Gray JE; Haura E; Chiappori A; Tanvetyanon T; Williams CC; Pinder-Schenck M; Kish JA; Kreahling J; Lush R; Neuger A; Tetteh L; Akar A; Zhao X; Schell MJ; Bepler G; Altiok S
    Clin Cancer Res; 2014 Mar; 20(6):1644-55. PubMed ID: 24429877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.